Pay in 4 interest-free payments of $7.29 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
In March 2026, Structure reported 44-week topline data from the ACCESS II Phase 2 study, showing placebo-adjusted weight loss of up to 16.3%, which the company described as the highest efficacy demonstrated among oral GLP-1 receptor agonists at that time point
Eur J Nutr 2015;54:251-63
These features are especially important where injection accuracy is critical, such as ocular injections and in cosmetic procedures
Range of motion during daily activities increases
US$ 20.64
US$ 21.13
US$ 28.21
US$ 20.47
US$ 26.89
US$ 23.23
%20powder-1.png)
US$ 20.46
US$ 23.54
US$ 26.51
